Naftopidil-d7

Naftopidil-d7 (KT-611-d7) is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

Product Specifications

Product Name Alternative

KT-611-d7 ; BM-15275-d7

UNSPSC

12352005

Target

Adrenergic Receptor; Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cardiovascular Disease; Endocrinology

Smiles

OC(CN1CCN(CC1)C2=C(OC)C=CC=C2)COC3=C([2H])C([2H])=C([2H])C4=C3C([2H])=C([2H])C([2H])=C4[2H]

Molecular Formula

C24H21D7N2O3

Molecular Weight

399.53

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]R Takei, et al. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol. 1999 Apr;79 (4) :447-54.|[3]Yasuhide Hori, et al. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila) . 2011 Jan;4 (1) :87-96.